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Abstract 
The aim of this multi-institutional study was to identify predictors of residual high-grade (HG) 
disease at re-transurethral resection (reTUR) in a large cohort of primary T1 HG/Grade 3 (G3) 
bladder cancer patients. 
A total of 1155 patients with primary T1 HG/G3 bladder cancer from 13 academic institutions that 
underwent a reTUR within 6 weeks after first TUR were evaluated. Logistic regression analysis was 
performed to assess the association of predictive factors with residual HG at reTUR. 
Residual HG cancer was found in 288 (24.9%) of patients at reTUR. Patients presenting residual HG 
cancer were more likely to have carcinoma in situ (CIS) at first resection (p<0.001), multiple tumors 
(p=0.02), and tumor size larger than 3 cm (p=0.02). Residual HG disease at reTUR was associated 
with increased preoperative neutrophil-to-lymphocytes ratio (NLR) (p=0.006) and body mass index 
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(BMI)>=25 kg/m2. On multivariable analysis, independent predictors for HG residual disease at 
reTUR were tumor size >3cm (OR = 1.37; 95% CI: 1.02-1.84, p=0.03), concomitant CIS (OR 
1.92; 95% CI: 1.32-2.78, p=0.001), being overweight (OR= 2.08; 95% CI: 1.44-3.01, p<0.001) and 
obesity (OR 2.48; 95% CI: 1.64-3.77, p<0.001). 
A reTUR in high grade T1 bladder cancer is mandatory as about 25% of patients, presents residual 
high grade disease. Independent predictors to identify patients at risk of residual high grade disease 
after a complete TUR include tumor size, presence of carcinoma in situ, and BMI >=25 kg/m2. 
Key words: bladder cancer, neutrophil-to-lymphocytes ratio, re-transurethral resection, high-grade 
Introduction 
Transurethral resection of bladder tumor (TUR) 
is considered the gold standard for the management 
of non-muscle invasive bladder cancer (NMIBC), 
followed by adjuvant intravesical therapy according 
to risk stratification [1,2]. A repeat TUR (reTUR) is 
now considered an essential step to obtain complete 
tumor resection and appropriate staging in T1 stage 
disease [3]. 
Most national and international guidelines 
recommend reTUR[1], mainly due to high prevalence 
of residual tumor found after reTUR and its clinical 
implications[4]. Nevertheless, controversy on the 
topic still exists as some argued that reTUR may not 
be needed when an adequate first TUR has been 
performed [5]. 
The aim of this multi-institutional study was to 
identify predictors of residual high-grade (HG) 
disease at reTUR in a large cohort of primary T1 
HG/Grade 3(G3) NMIBC patients. 
Material and Methods 
Patient selection and data collection 
Institutional-review-board approval was 
obtained in each institution. Inclusion criteria were 
established before data collection: (1) pathological T1 
HG/G3 confirmed after first TUR; (2) a reTUR 
performed within 4 to 6 weeks after a complete first 
TUR (defined by confirmed presence of muscularis 
propria on pathology); (3) pretreatment NLR 
available prior to TUR; (4) history of smoking status 
and BMI.  
Patients with systemic diseases that could 
interfere with NLR at the time of TUR (such as 
leukemia, lymphoma, chronic inflammatory diseases, 
or autoimmune diseases) were excluded. BMI was 
defined as the weight in kilograms divided by the 
square of the height in meters (kg/m2), and was 
categorized in underweight (<18.5 kg/m2), normal 
weight (18.5-24.99 kg/m2), overweight (25-29.99 
kg/m2) and obese (≥30 kg/m2) according to the 
International Classification of adult underweight, 
overweight and obesity according to BMI [6]. 
A total of 1155 HGT1 NMIBC consecutive 
patients from 13 academic institutions that underwent 
a reTUR within 6 weeks after first TUR between 1st 
January 2002 and 31st December 2012 were included. 
Patients who had MIBC at subsequent reTUR were 
excluded. There was no interim intravesical therapy 
after initial TUR. Demographical, clinical and 
pathological data of first and second resection were 
collected and entered in a computerized database. 
Histology was performed by experienced 
uro-pathology at each institution. Tumors were 
classified histologically using the 1973 World Health 
Organization (WHO) and tumor, node and metastasis 
classifications [7]. Protocol of reTUR included tumor 
scar and base resection, together with the bladder 
neck (for CIS) and red bladder patches. ReTUR was 
generally performed by the same urologist who 
performed the first TUR of bladder tumor [8].  
Statistical analysis 
Associations of T1 HG/G3 at reTUR with 
categorical variables were assessed using χ2 tests 
while differences in continuous variables were 
analyzed using t test after assessing normality of the 
distribution (Kolmogorov-Smirnov). Logistic 
regression analysis was performed to assess the 
association of several predictive factors (age, gender, 
smoking status, size, multifocality, concomitant CIS, 
NLR, and BMI) with residual HG at reTUR. All p 
values were two-sided, and statistical significance 
was defined as a p < 0.05. Statistical analyses were 
performed using Stata 11.0 statistical software (Stata 
Corp., College Station, TX, USA).  
Results 
Association of HG/G3 at reTUR with clinic and 
pathological characteristics 
Residual HG disease was found in 288 (24.9%) of 
patients after reTUR. Patients with residual HG 
disease at reTUR were more likely to have 
concomitant Carcinoma in Situ (CIS) at first resection 
(20.1% vs. 11.3%, p<0.001), multiple tumors (50.4% vs. 
42.8%, p=0.02), and tumor size larger than 3 cm (70.5% 
vs. 62.7%, p=0.01) and increased pre-treatment (prior 
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to initial TUR) neutrophil-to-lymphocytes ratio (NLR) 
(57.3% vs. 47.8%, p=0.006). In terms of body mass 
index (BMI) stratification, overweight and obese 
patients were more likely to have residual HG disease 
at reTUR (p<0.001, Table 1). 
Predictive factors for residual HG disease at 
reTUR 
On univariable analysis, predictive factors for 
residual HG disease at reTUR were size>3 cm (OR 
1.41, p=0.01), multifocality (OR 1.35, p=0.02), 
concomitant CIS (OR 1.97, p<0.001), NLR>3 (OR 1.46, 
p=0.006) and BMI (overweight and and obese, 
p<0.001; OR 2.16 and 2.57, respectively). On 
multivariable analysis, size > 3 cm (OR 1.37, p=0.03), 
concomitant CIS (OR 1.92, p=0.001), overweight (OR 
2.08, p<0.001) and obesity (OR 2.48, p<0.001) status 
according to BMI remained as significant independent 
predictors for HG residual disease at reTUR (Table 2). 
 
Table 1. Association of HG/G3 on reTUR with clinical and pathologic characteristics of 1155 patients after primary T1 HG/G3 NMIBC 
  All patients No tumor/G2  HG/G3  p-value 
Total, n (%) 1155 867 (75.1) 288 (24.9)  
Age Mean (range) 70.33 (46-88) 70.32 70.3 0.97 
Gender, n (%)     
Male 957 (82.9) 715 (82.5) 242 (84) 0.54 
Female 198 (17.1) 152 (17.5) 46 (16)  
Smoking status     
never 328 (28.4) 252 (29.1) 76 (26.4) 0.45 
current 549 (47.5) 403 (46.4) 146 (50.7)  
former 278 (24.1) 212(24.5) 66 (22.9)  
Multifocality, n (%)     
single 639 (55.3) 496 (57.2) 143 (49.6) 0.02 
multiple 516 (44.7) 371 (42.8) 145 (50.4)  
Size, n (%)     
<=3cm 408 (35.3) 323 (37.3) 85 (29.5) 0.01 
>3 cm 747 (64.7) 544 (62.7) 203 (70.5)  
Concomitant carcinoma in situ, n (%)     
No 999 (86.5) 769 (88.7) 230 (79.9) <0.001 
Yes 156 (13.5) 98 (11.3) 58 (20.1)  
NLR, n (%)     
<=3 575 (49.8) 452 (52.1) 123 (42.7) 0.006 
>3  580 (50.2) 415 (47.8) 165 (57.3)  
BMI normal 337 (29.2) 285 (32.9) 52 (18.1) <0.001 
underweight 24 (2.1) 22 (2.5) 2 (0.7)  
overweight 534 (46.2) 383 (44.2) 151 (52.4)  
obese 260 (22.5) 177 (20.4) 83 (28.8)  
TUR: transurethral resection of bladder tumor, NMIBC: non-muscle invasive bladder cancer; NLR: neutrophil-to-lymphocytes ratio, BMI: body mass index 
 
 
Table 2. Univariate and multivariate logistic regression analyses for predicting residual high grade disease at reTUR in 1155 patients with 
primary T1HG/G3 NMIBC. 
Preoperative prognostic 
factors 
HG/G3 on reTUR 
Univariate Multivariate 
OR 95% CI p OR 95% CI p 
Age (continuous) 0.99 0.98-1.01 0.97 1 0.98-1.01 0.86 
Gender (male vs. female) 0.89 0.62-1.28 0.54 0.86 0.59-1.25 0.44 
Smoking status 
 
Never smoker is reference 
Current smoker 1.2 0.87-1.65 0.26 1.14 0.82-1.59 0.42 
Former smoker 1.03 0.7-1.5 0.86 1.13 0.76-1.69 0.53 
Multifocality (Yes. Vs. no) 1.35 1.03-1.77 0.02 1.26 0.96-1.66 0.09 
Size >3 cm vs. <= 3 cm 1.41 1.06-1.89 0.01 1.37 1.02-1.84 0.03 
Concomitant CIS (Yes vs. no) 1.97 1.38-2.82 <0.001 1.92 1.32-2.78 0.001 
NLR >3 vs. <= 3 1.46 1.11-1.91 0.006 1.12 0.83-1.5 0.44 
BMI Normal weight is reference 
underweight 0.49 0.11-2.18 0.35 0.53 0.12-2.36 0.4 
overweight 2.16 1.52-3.06 <0.001 2.08 1.44-3.01 <0.001 
obese 2.57 1.73-3.81 <0.001 2.48 1.64-3.77 <0.001 
TURBT: transurethral resection of bladder tumor, OR: Odds ratio, CI: Confidence interval 
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Discussion 
We showed that residual HG disease at re-TUR 
was reported in one out of four patients with initial 
T1HG NMIBC. It was associated with worse clinical 
characteristics such as increased BMI and increased 
pretreatment NLR and worse pathological features 
such as multifocality, tumor size >3 cm and presence 
of concomitant CIS at first TUR in a cohort of patients 
with primary T1 HG/G3 NMIBC. Moreover, 
independent predictors for residual HG disease at 
reTUR were size >3 cm, presence of concomitant CIS 
and BMI >=25 kg/m2. 
In a mono-center study, multiplicity, T1 and HG 
in the initial TUR were shown to be independent risk 
factors for residual tumors at reTUR [9]. In another 
study that included 179 patients with NMIBC, a high 
risk of recurrence according to the EAU risk score 
classification at the initial TUR and multifocality were 
associated with higher rates of residual tumor [10].  
In our retrospective study, we showed that in 
patients wth high-risk tumors (i.e. HGT1), BMI may 
contribute to identify patients that could have 
residual HG disease at reTUR. 
Certainly, a complete and correctly performed 
TUR is essential to achieve good prognosis as the 
residual tumor rate at reTUR can be as high as 47% 
(95% CI: 0.41–0.53) [11]. Re-TURBT is indicated and 
should be routinely performed in T1 NMIBC also to 
reduce the risk of under-staging and missing 
MIBC[3]. The presence of a high-risk cancer at first 
TUR was shown to be an independent risk factor for 
residual disease at reTUR in several studies [10,12]. 
Similarly, concomitant CIS also significantly 
correlated with incidence of residual tumor in a 
prospective study that included 52 patients, while the 
absence of muscularis propria in the primary TUR 
specimen was associated with upstaging to MIBC [13]. 
In our cohort, one of the inclusion criteria was the 
presence of muscle tissue at the first TUR. Takaoka et 
al. showed that CIS was also a risk factor for residual 
tumors at reTUR in a cohort that included HGT1 
patients [14].Tumor multiplicity at the first resection 
was found to be an independent risk factor for stage 
pT1 or worse tumor at re-TUR in a multi-institutional 
study that included Japanese patients [15]. Moreover, 
one study that included 188 African patients with T1 
NMIBC found that male gender along with 
multifocality are risk factors for residual tumors at 
reTUR [16]. 
Liu et al. found out that patients with altered p53 
and E-cadherin expression were more likely to have 
residual tumors [17]. Lodde et al found that a positive 
cytology prior to second TUR was associated with 
positive re- TUR[18]. 
One recently published meta-analysis showed a 
nonlinear positive relationship between BMI and BC 
risk, with a a 5 kg/m2 increment of BMI being 
associated with a 3.1 % increase of bladder cancer risk 
[19]. Patients diagnosed with clinical HGT1 urothelial 
carcinoma of the bladder who are obese have worse 
cancer specific outcomes compared to their non-obese 
counterparts [20]. To our knowledge, the study 
presented here is the first that shows that increased 
BMI is associated with residual HG disease after a 
complete TUR. Although the potential 
etiopathogenetic association with obesity is 
intriguing, we acknowledge that this finding may be 
due to the difficulty of transurethral resection in case 
of overweight and obese patients, as was shown also 
in case of transurethral resection of the prostate [21]. 
A higher NLR was reported to be associated 
with T1 vs. Ta tumors tumor stage at the time of TUR 
(mean 3.9 vs. 2.5)[22].In our cohort, NLR was a 
predictor of residual HG disease at reTUR at 
univariable analysis but did not retain its significance 
at multivariable analysis. Indeed, in T1 vs. Ta NMIBC 
inflammatory markers levels are higher, and 
associated with progression [23] and recurrence [24]. 
These findings have also been replicated in patients 
with MIBC [25,26]. However, prospectively collected 
data showed that pretreatment NLR was not 
associated with overall survival in MIBC patients after 
radical cystectomy, which is consistent with our 
findings [27]. 
The limitations of the present study are those 
typical of retrospective studies, including the 
presence of a selection bias, as well as heterogenous 
surgeon expertise and surgical technique. 
Furthermore, patients were not assessed for 
consumption of steroids, presence of infection or 
thromboembolism, which may affect NLR, nor were 
tumor location and lymph-vascular invasion included 
in the multivariable analysis. Despite these 
limitations, we believe that our study provides 
evidence indicating a potential association between 
obesity and risk of residual disease after TUR, which 
should be further explored in order to assess its 
potential practical clinical implications as well as its 
etiopathogenetic basis.  
Conclusion 
Re-TURBT should be routinely performed in T1 
NMIBC to reduce the risk of under-staging and 
missing MIBC. A re-TUR in high grade T1 bladder 
cancer is mandatory considering that about 25% of 
patients present residual high grade disease. 
Independent predictors to identify patients at risk of 
residual high grade disease after a complete TUR are 
tumor size, presence of carcinoma in situ, and BMI 
>=25 kg/m2. 
 Journal of Cancer 2018, Vol. 9 
 
http://www.jcancer.org 
4254 
Acknowledgements 
This study was supported by “Fondazione 
Muto”, Naples-Italy. M.D.V is supported by the 
Scholarship Foundation of the Republic of Austria - 
OeAD and by the EUSP Scholarship - European 
Association of Urology. 
Conflict of interest 
The authors declare that they have no conflict of 
interest. 
References 
1.  Richterstetter M, Wullich B, Amann K, Haeberle L, Engehausen DG, Goebell 
PJ, Krause FS. The value of extended transurethral resection of bladder 
tumour (TURBT) in the treatment of bladder cancer. BJU Int. 2012; 110: E76-79. 
doi: 10.1111/j.1464-410X.2011.10904.x. 
2.  Babjuk M, Bohle A, Burger M, Comperat E, Kaasinen E, Palou J, Rouprêt M, 
van Rhijn BW, Shariat SF, Sylvester R, Zigeuner R. Guidelines on 
non-muscle-invasive Bladder Cancer (Ta,T1 and CIS). EAU Guidelines. 
European Association of Urology; 2015.  
3.  Naselli A, Hurle R, Paparella S, Buffi NM, Lughezzani G, Lista G, Casale P, 
Saita A, Lazzeri M, Guazzoni G. Role of Restaging Transurethral Resection for 
T1 Non-muscle invasive Bladder Cancer: A Systematic Review and 
Meta-analysis. Eur Urol Focus. 2017; . doi: 10.1016/j.euf.2016.12.011. 
4.  Schwaibold HE, Sivalingam S, May F, Hartung R. The value of a second 
transurethral resection for T1 bladder cancer. Bju Int. 2006; 97: 1199–201. doi: 
10.1111/j.1464-410X.2006.06144.x. 
5.  Brausi MA. Challenging the EAU Guidelines Regarding Early Repeat 
Transurethral Resection. Eur Urol Suppl. 2011; 10: E5–7. doi: 
10.1016/j.eursup.2011.04.003. 
6.  Flegal KM, Carroll MD, Ogden CL, Curtin LR. Prevalence and trends in 
obesity among US adults, 1999-2008. JAMA. 2010; 303: 235–41. doi: 
10.1001/jama.2009.2014. 
7.  Balan D, Martha O, Chibelean CB, Tataru S, Voidezan S, Sin A, Matei VD, 
Vartolomei MD, Lucarelli G, Cioffi A, Del Giudice F, De Berardinis E, Borda A, 
et al. Comparison of 10-year overall survival between patients with G1 and G2 
grade Ta bladder tumors. Medicine (Baltimore). 2018; 97: e0522. doi: 
10.1097/MD.0000000000010522. 
8.  Del Zingaro M, Bruno R, Nunzi E, Porena M, Mearini L. First and second 
transurethral resections in intermediate-high risk bladder cancer: impact of 
the surgeon’s volume on the recurrence and progression of primary bladder 
cancer. Minerva Urol E Nefrol Ital J Urol Nephrol. 2016; 68: 194–203.  
9.  Cao M, Yang G, Pan J, Sun J, Chen Q, Chen Y, Chen H, Xue W. Repeated 
transurethral resection for non-muscle invasive bladder cancer. Int J Clin Exp 
Med. 2015; 8: 1416–9.  
10.  Hartinger J, Häußermann R, Olbert P, Hofmann R, Hegele A. [Predictors for 
presence of residual tumor in follow-up transurethral resection of bladder 
tumors: single center results]. Urol Ausg A. 2013; 52: 557–61. doi: 
10.1007/s00120-012-3109-x. 
11.  Vianello A, Costantini E, Del Zingaro M, Bini V, Herr HW, Porena M. 
Repeated White Light Transurethral Resection of the Bladder in 
Nonmuscle-Invasive Urothelial Bladder Cancers: Systematic Review and 
Meta-Analysis. J Endourol. 2011; 25: 1703–12. doi: 10.1089/end.2011.0081. 
12.  Husillos Alonso A, Rodríguez Fernández E, Herranz Amo F, López López E, 
Aragón Chamizo J, Ramírez Martínez D, Durán Merino R, Hernández 
Fernández C. The need for re-TUR of the bladder in non-muscle invasive 
bladder cancer: risk factors of tumor persistence in re-TUR specimens. 
Minerva Urol E Nefrol Ital J Urol Nephrol. 2014; 66: 233–40.  
13.  Gill TS, Das RK, Basu S, Dey RK, Mitra S. Predictive factors for residual tumor 
and tumor upstaging on relook transurethral resection of bladder tumor in 
non-muscle invasive bladder cancer. Urol Ann. 2014; 6: 305–8. doi: 
10.4103/0974-7796.140990. 
14.  Takaoka E, Matsui Y, Inoue T, Miyazaki J, Nakashima M, Kimura T, Oikawa T, 
Kawai K, Yoshimura K, Habuchi T, Ogawa O, Nishiyama H. Risk factors for 
intravesical recurrence in patients with high-grade T1 bladder cancer in the 
second TUR era. Jpn J Clin Oncol. 2013; 43: 404–9. doi: 10.1093/jjco/hyt016. 
15.  Kamiya N, Suzuki H, Suyama T, Kobayashi M, Fukasawa S, Sekita N, Mikami 
K, Nihei N, Naya Y, Ichikawa T. Clinical outcomes of second transurethral 
resection in non-muscle invasive high-grade bladder cancer: a retrospective, 
multi-institutional, collaborative study. Int J Clin Oncol. 2017; 22: 353–8. doi: 
10.1007/s10147-016-1048-z. 
16.  Turk H, Un S, Isoglu CS, Karabicak M, Ergani B, Yoldas M, Tarhan H, Zorlu F. 
Factors that predict residual tumors in re-TUR patients. Afr J Urol. 2016; 22: 
67–70. doi: 10.1016/j.afju.2015.07.004. 
17.  Liu W, Qi L, Zu X, Li Y, He W, Tong S, Chen M. A preoperative marker panel 
for the prediction of residual tumor and the decision making for repeat 
transurethral resection. Urol Oncol. 2015; 33: 165.e9-14. doi: 
10.1016/j.urolonc.2015.01.006. 
18.  Lodde M, Mayr R, Martini T, Comploj E, Palermo S, Trenti E, Hanspeter E, 
Fritsche HM, Mian C, Pycha A. Positive urine cytology and carcinoma in situ 
prior to second transurethral resection of the bladder correlate with positive 
second resection histology and the need for subsequent cystectomy. World J 
Urol. 2012; 30: 841–6. doi: 10.1007/s00345-012-0975-1. 
19.  Zhao L, Tian X, Duan X, Ye Y, Sun M, Huang J. Association of body mass 
index with bladder cancer risk: a dose-response meta-analysis of prospective 
cohort studies. Oncotarget. 2017; 8: 33990–4000. doi: 
10.18632/oncotarget.16722. 
20.  Kluth LA, Xylinas E, Crivelli JJ, Passoni N, Comploj E, Pycha A, Chrystal J, 
Sun M, Karakiewicz PI, Gontero P, Lotan Y, Chun FK-H, Fisch M, et al. 
Obesity is associated with worse outcomes in patients with T1 high grade 
urothelial carcinoma of the bladder. J Urol. 2013; 190: 480–6. doi: 
10.1016/j.juro.2013.01.089. 
21.  Gacci M, Sebastianelli A, Salvi M, De Nunzio C, Tubaro A, Vignozzi L, Corona 
G, McVary KT, Kaplan SA, Maggi M, Carini M, Serni S. Central obesity is 
predictive of persistent storage lower urinary tract symptoms (LUTS) after 
surgery for benign prostatic enlargement: results of a multicentre prospective 
study. BJU Int. 2015; 116: 271–7. doi: 10.1111/bju.13038. 
22.  Tazeh NN, Canter DJ, Damodaran S, Rushmer T, Richards KA, Abel EJ, 
Jarrard DF, Downs TM. Neutrophil to Lymphocyte Ratio (NLR) at the Time of 
Transurethral Resection of Bladder Tumor: A Large Retrospective Study and 
Analysis of Racial Differences. Bladder Cancer Amst Neth. 2017; 3: 89–94. doi: 
10.3233/BLC-160085. 
23.  Martha O, Porav-Hodade D, Bălan D, Tătaru OS, Sin A, Chibelean CB, 
Vartolomei MD. Easily Available Blood Test Neutrophil-To-Lymphocyte Ratio 
Predicts Progression in High-Risk Non-Muscle Invasive Bladder Cancer. Rev 
Romana Med Lab. 2017; 25: 181–9. doi: 10.1515/rrlm-2017-0016. 
24.  Mbeutcha A, Shariat SF, Rieken M, Rink M, Xylinas E, Seitz C, Lucca I, 
Mathieu R, Rouprêt M, Briganti A, Karakiewicz PI, Klatte T. Prognostic 
significance of markers of systemic inflammatory response in patients with 
non-muscle-invasive bladder cancer. Urol Oncol. 2016; 34: 483.e17-483.e24. 
doi: 10.1016/j.urolonc.2016.05.013. 
25.  Masson-Lecomte A, Rava M, Real FX, Hartmann A, Allory Y, Malats N. 
Inflammatory biomarkers and bladder cancer prognosis: a systematic review. 
Eur Urol. 2014; 66: 1078–91. doi: 10.1016/j.eururo.2014.07.033. 
26.  Lucca I, Jichlinski P, Shariat SF, Rouprêt M, Rieken M, Kluth LA, Rink M, 
Mathieu R, Mbeutcha A, Maj-Hes A, Fajkovic H, Briganti A, Seitz C, et al. The 
Neutrophil-to-lymphocyte Ratio as a Prognostic Factor for Patients with 
Urothelial Carcinoma of the Bladder Following Radical Cystectomy: 
Validation and Meta-analysis. Eur Urol Focus. 2016; 2: 79–85. doi: 
10.1016/j.euf.2015.03.001. 
27.  Ojerholm E, Smith A, Hwang W-T, Baumann BC, Tucker KN, Lerner SP, 
Mamtani R, Boursi B, Christodouleas JP. Neutrophil-to-Lymphocyte Ratio as a 
Bladder Cancer Biomarker: Assessing Prognostic and Predictive Value in 
SWOG 87 10. Cancer. 2017; 123: 794–801. doi: 10.1002/cncr.30422. 
 
